blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3299031

EP3299031 - METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.04.2023
Database last updated on 17.07.2024
FormerThe patent has been granted
Status updated on  06.05.2022
FormerGrant of patent is intended
Status updated on  15.11.2021
FormerExamination is in progress
Status updated on  14.03.2019
FormerRequest for examination was made
Status updated on  28.09.2018
FormerThe application has been published
Status updated on  23.02.2018
Most recent event   Tooltip09.02.2024Lapse of the patent in a contracting state
New state(s): IT		published on 13.03.2024  [2024/11]
Applicant(s)For all designated states
Immunolight, LLC
1901 St. Antoine Street
Detroit, MI 48226 / US
[2018/13]
Inventor(s)01 / BOURKE, Frederic, A.
P.O. Box 10117
Aspen, CO 81612 / US
 [2021/50]
Former [2018/19]01 / BOURKE, Frederik, A.
P.O. Box 10117
Aspen, CO 81612 / US
Former [2018/13]01 / BOURKE, Frederik, A.
17 Fort Hills Lane
Greenwich, CT Connecticut 06831 / US
Representative(s)Tostmann, Holger Carl
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2018/13]
Application number, filing date17200448.307.04.2008
[2018/13]
Priority number, dateUS20070910663P08.04.2007         Original published format: US 910663 P
US2007093565506.11.2007         Original published format: US 935655
[2018/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3299031
Date:28.03.2018
Language:EN
[2018/13]
Type: B1 Patent specification 
No.:EP3299031
Date:08.06.2022
Language:EN
[2022/23]
Search report(s)(Supplementary) European search report - dispatched on:EP28.02.2018
ClassificationIPC:A61K41/00
[2018/13]
CPC:
A61K31/35 (EP,KR,US); A61K31/37 (EP,KR,US); A61K41/0071 (KR,US);
A61F7/00 (KR,US); A61H23/00 (US); A61K31/366 (EP,US);
A61K31/714 (EP,KR,US); A61K41/00 (EP,US); A61K41/0066 (EP,KR,US);
A61K41/008 (EP,KR,US); A61K45/06 (EP,KR,US); A61K47/02 (US);
A61N2/02 (KR,US); A61N5/062 (KR,US); A61N5/10 (US);
A61P31/04 (EP); A61P31/12 (EP); A61P35/00 (EP);
A61P37/02 (EP); A61P37/04 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61P7/00 (EP); A61K2300/00 (KR);
A61N2005/0656 (US); A61N2005/1089 (US); A61N2005/1098 (US) (-)
C-Set:
A61K31/35, A61K2300/00 (EP,US);
A61K41/00, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/44]
Former [2018/13]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ZELLPROLIFERATIONSKRANKHEITEN[2018/13]
English:METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS[2018/13]
French:PROCÉDÉS ET SYSTÈMES DE TRAITEMENT DES TROUBLES DE LA PROLIFÉRATION CELLULAIRE[2018/13]
Examination procedure07.11.2017Date on which the examining division has become responsible
19.09.2018Amendment by applicant (claims and/or description)
19.09.2018Examination requested  [2018/44]
18.03.2019Despatch of a communication from the examining division (Time limit: M04)
14.05.2019Reply to a communication from the examining division
27.08.2019Despatch of a communication from the examining division (Time limit: M06)
11.02.2020Reply to a communication from the examining division
31.03.2020Despatch of a communication from the examining division (Time limit: M04)
06.07.2020Reply to a communication from the examining division
12.02.2021Cancellation of oral proceeding that was planned for 10.06.2021
10.06.2021Date of oral proceedings (cancelled)
01.10.2021Cancellation of oral proceeding that was planned for 25.10.2021
25.10.2021Date of oral proceedings (cancelled)
16.11.2021Communication of intention to grant the patent
22.03.2022Fee for grant paid
22.03.2022Fee for publishing/printing paid
22.03.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08733147.6  / EP2150549
Opposition(s)10.03.2023No opposition filed within time limit [2023/20]
Fees paidRenewal fee
07.11.2017Renewal fee patent year 03
07.11.2017Renewal fee patent year 04
07.11.2017Renewal fee patent year 05
07.11.2017Renewal fee patent year 06
07.11.2017Renewal fee patent year 07
07.11.2017Renewal fee patent year 08
07.11.2017Renewal fee patent year 09
07.11.2017Renewal fee patent year 10
15.06.2018Renewal fee patent year 11
29.04.2019Renewal fee patent year 12
27.04.2020Renewal fee patent year 13
27.04.2021Renewal fee patent year 14
27.04.2022Renewal fee patent year 15
Penalty fee
Additional fee for renewal fee
30.04.201811   M06   Fee paid on   15.06.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
IT08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
SI08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
[2024/11]
Former [2023/25]AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
SI08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/21]AT08.06.2022
CZ08.06.2022
DK08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/12]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/11]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/09]AT08.06.2022
CZ08.06.2022
EE08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
RO08.06.2022
SK08.06.2022
BG08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/07]AT08.06.2022
ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
BG08.09.2022
GR09.09.2022
Former [2022/49]ES08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
BG08.09.2022
GR09.09.2022
Former [2022/47]ES08.06.2022
FI08.06.2022
LT08.06.2022
Documents cited:Search[XDI]US2002127224  (CHEN JAMES [US]) [XD] 1-5,8-10,13 * claims 1-136 * * paragraphs [0028] - [0123] * [I] 6,7,11,12,14-21;
 [XI]US2003022105  (PRASAD PARAS N [US], et al) [X] 1,3-5,8-10,13,14,17-20 * claims 170-203 * [I] 2,6,7,11,12,15,16,21;
 [XI]WO2006111971  (ARIEL UNIVERSITY RES AND DEV C [IL], et al) [X] 1,3-5,8-10,14 * claims 1-29 * * page 10 - page 11 * [I] 2,6,7,11,12,14-21;
 [XPI]US2007218049  (CHEN WEI [US], et al) [XP] 1,3-5,8-10,13 * claims 1-34 * * pages 48-132 * [I] 2,6,7,11,12,14-21;
 [E]WO2009114567  (IMMUNOLIGHT LLC [US], et al) [E] 1-21 * the whole document *;
 [E]WO2009124189  (IMMUNOLIGHT LLC [US], et al) [E] 1-21 * the whole document *;
 [T]WO2017070197  (IMMUNOLIGHT LLC [US], et al) [T] 1-21* the whole document *;
 [XI]  - SEHOON KIM ET AL, "Organically Modified Silica Nanoparticles Co-encapsulating Photosensitizing Drug and Aggregation-Enhanced Two-Photon Absorbing Fluorescent Dye Aggregates for Two-Photon Photodynamic Therapy", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20070301), vol. 129, no. 9, doi:10.1021/ja0680257, ISSN 0002-7863, pages 2669 - 2675, XP055128463 [X] 1,3-5,8-10,13,14,17-19 * abstract * * in vitro studied with tumor cells; page 2671 * [I] 2,6,7,11,12,15,16,20,21

DOI:   http://dx.doi.org/10.1021/ja0680257
 [T]  - MARK OLDHAM ET AL, "X-Ray Psoralen Activated Cancer Therapy (X-PACT)", PLOS ONE, (20160901), vol. 11, no. 9, doi:10.1371/journal.pone.0162078, page e0162078, XP055450449 [T] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0162078
Examination   - R. Gerl, "Apoptosis in the development and treatment of cancer", Carcinogenesis, (20040916), vol. 26, no. 2, doi:10.1093/carcin/bgh283, pages 263 - 270, XP055715321

DOI:   http://dx.doi.org/10.1093/carcin/bgh283
by applicantUS124
 US7045
 US4522811
 US4748120
 US4838852
 US4979935
 US5216176
 US5829448
 US5980954
 US5984887
 US6204058
 US6235508
 US2002127224
 US6569467
 WO03049801
 US6669965
 US6849058
 US6908591
    - CHEN et al., J. Nanosci. and Nanotech., (20060000), vol. 6, pages 1159 - 1166
    - KIM et al., JACS, (20070000), vol. 129, pages 2669 - 2675
    - W. R. MIDDEN, Psoralen DNA photobiology, CRC press, (19880000), vol. II, page 1
    - Psoralen DNA Photobiology, CRC Press, Inc., vol. I
    - COMER C., "Determination of [3H]- and [14C] hematoporphyrin derivative distribution in malignant and normal tissue", Cancer Res, (19790000), vol. 3 9, pages 146 - 15 1
    - YOUNG SW et al., "Lutetium texaphyrin (PCI-0123) a near-infrared, water-soluble photosensitizer", Photochem Photobiol, (19960000), vol. 63, doi:doi:10.1111/j.1751-1097.1996.tb09647.x, pages 892 - 897, XP000613687

DOI:   http://dx.doi.org/10.1111/j.1751-1097.1996.tb09647.x
    - BERENBAUM MC et al., "Meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumor photosensitisers with favourable selectivity", Br J Cancer, (19860000), vol. 54, doi:doi:10.1038/bjc.1986.232, pages 717 - 725, XP055128462

DOI:   http://dx.doi.org/10.1038/bjc.1986.232
    - "Photodynamic therapy in oncology: mechanisms and clinical use", J Natl Cancer Inst, (19930000), vol. 85, pages 443 - 456
    - FOOTE CS, "Mechanisms of photooxygenation", Proa Clin Biol Res, (19840000), vol. 170, pages 3 - 18
    - J. Am. Chem. Soc., (20050000), vol. 127, pages 9760 - 9768
    - YOUNG; DEITERS, "Photochemical Control of Biological Processes", Org. Biomol. Chem., (20070000), vol. 5, doi:doi:10.1039/B616410M, pages 999 - 1005, XP008142183

DOI:   http://dx.doi.org/10.1039/B616410M
    - "Photochemical Hammerhead Ribozyme Activation", Bioorganic & Medicinal Chemistry Letters, (20060000), vol. 16, no. 10, pages 2658 - 2661
    - GIACCHETTI et al., Journal of Clinical Oncology, (20060801), vol. 24, no. 22, pages 3562 - 3569
    - M. E. VAN EIJKEREN et al., Acta Oncologica, (19920000), vol. 31, page 539
    - K. KOBOTA et al., J. Nucl. Med., (19910000), vol. 32, page 2118
    - K. HIGASHI et al., J. Nucl. Med., (19930000), vol. 34, page 773
    - B. A. COOPER et al., Nature, (19610000), vol. 191, page 393
    - H. FLODH, Acta Radiol. Suppl., (19680000), vol. 284, page 55
    - L. BLOOMQUIST et al., Experientia, (19690000), vol. 25, page 294
    - J. LINDEMANS et al., Exp. Cell. Res., (19890000), vol. 184, page 449
    - T. AMAGASAKI et al., Blood, (19900000), vol. 26, page 138
    - J. A. BEGLY et al., J. Cell Physiol., (19930000), vol. 156, page 43
    - D. SWANSON et al., Pharmaceuticals in Medical Imaging, MacMillan Pub. Co., (19900000), page 621 628
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.